{"nctId":"NCT02113241","briefTitle":"Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion","startDateStruct":{"date":"2014-04","type":"ACTUAL"},"conditions":["Metabolic Syndrome X"],"count":24,"armGroups":[{"label":"Dapagliflozin","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Dapagliflozin","otherNames":["Forxiga"]},{"name":"Placebo","otherNames":["Calcined magnesium"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients both sexes\n* Age between 30 and 60 years\n* Metabolic Syndrome according to the IDF criteria\n* Waist circumference\n* Man ≥90 cm\n* Woman ≥80 cm\n* And two of the following criteria\n* High density lipoprotein\n* Man ≤40 mg/dL\n* Woman ≤50 mg/dL\n* Fasting glucose ≥100 mg/dL\n* Triglycerides ≥150 mg/dL\n* Blood pressure ≥130/85 mmHg\n* Informed consent signed\n\nExclusion Criteria:\n\n* Women with confirmed or suspected pregnancy\n* Women under lactation and/or puerperium\n* Hypersensibility to SGLT2 inhibitors\n* Physical impossibility for taking pills\n* Known uncontrolled renal, hepatic, heart or thyroid diseased\n* Previous treatment for the metabolic syndrome components\n* Body Mass Index ≥39.9 kg/m2\n* Fasting glucose ≥126 mg/dL\n* Triglycerides ≥500 mg/dL\n* Total cholesterol ≥240 mg/dL\n* Low density lipoprotein (c-LDL) ≥190 mg/dL\n* Blood Pressure ≥140/90 mmHg","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Waist Circumference at Week 12.","description":"The waist circumference is going to be evaluated at week 12 with a flexible tape with standardized techniques.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":"8.9"},{"groupId":"OG001","value":"97.2","spread":"6.9"}]}]}]},{"type":"PRIMARY","title":"Triglycerides Levels at Week 12.","description":"The triglycerides levels are going to be evaluated at week 12 with enzymatic-colorimetric techniques.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.8"},{"groupId":"OG001","value":"1.7","spread":"0.6"}]}]}]},{"type":"PRIMARY","title":"High Density Lipoprotein (c-HDL) Levels at Week 12.","description":"The c-HDL levels are going to be evaluated at week 12 with enzymatic/colorimetric techniques.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"0.2"},{"groupId":"OG001","value":"1.3","spread":"0.2"}]}]}]},{"type":"PRIMARY","title":"Glucose Levels at Minute 0 at Week 12.","description":"The fasting glucose (0') levels are going to be evaluated at week 12 with enzymatic/colorimetric techniques.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"1.1"},{"groupId":"OG001","value":"5.8","spread":"0.7"}]}]}]},{"type":"PRIMARY","title":"Systolic Blood Pressure at Week 12.","description":"The systolic blood pressure is going to be evaluated at week 12 with a digital sphygmomanometer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":"10"},{"groupId":"OG001","value":"121","spread":"13"}]}]}]},{"type":"PRIMARY","title":"Diastolic Blood Pressure at Week 12.","description":"The diastolic blood pressure is going to be evaluated at week 12 with a digital sphygmomanometer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":"8"},{"groupId":"OG001","value":"79","spread":"10"}]}]}]},{"type":"PRIMARY","title":"Insulinogenic Index (Total Insulin Secretion) at Week 12.","description":"The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.\n\nTotal insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion at week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.11"},{"groupId":"OG001","value":"0.99","spread":"0.38"}]}]}]},{"type":"PRIMARY","title":"Stumvoll Index (First Phase of Insulin Secretion) at Week 12.","description":"Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.\n\nFirst phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the frst phase of insulin secretion at week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1463","spread":"879"},{"groupId":"OG001","value":"2198","spread":"996"}]}]}]},{"type":"PRIMARY","title":"Matsuda Index (Total Insulin Sensitivity) at Week 12.","description":"Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index \\[10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)\\]. The entered values reflect the insulin sensitivity at week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"1.4"},{"groupId":"OG001","value":"1.6","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Body Weight at Week 12.","description":"The weight it's going to be measured at week 12 with a bioimpedance balance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":"12.8"},{"groupId":"OG001","value":"79.6","spread":"11.3"}]}]}]},{"type":"SECONDARY","title":"Body Mass Index at Week 12","description":"The Body Mass index it's going to be calculated at week 12 with the Quetelet index.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.6","spread":"3.6"},{"groupId":"OG001","value":"32.1","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Fat Mass at Week 12.","description":"The fat mass is going to be evaluated at week 12 through bioimpedance.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.7","spread":"9.2"},{"groupId":"OG001","value":"34.4","spread":"7.3"}]}]}]},{"type":"SECONDARY","title":"Total Cholesterol at Week 12","description":"The total cholesterol will be estimated by standardized techniques at week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"0.7"},{"groupId":"OG001","value":"4.9","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Low Density Lipoproteins (c-LDL) at Week 12","description":"The c-LDL levels are going to be measured at week 12 with standardized techniques.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"0.5"},{"groupId":"OG001","value":"2.8","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Alanine Aminotransferase (ALT) at Week 12.","description":"The ALT hepatic transaminase levels are going to be measured at week 12 with standardized techniques.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.1","spread":"15.9"},{"groupId":"OG001","value":"38.1","spread":"25.0"}]}]}]},{"type":"SECONDARY","title":"Aspartate Aminotransferase (AST) at Week 12.","description":"The hepatic transaminase AST will be evaluated with standardized methods at week 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","spread":"14.5"},{"groupId":"OG001","value":"29.5","spread":"16.5"}]}]}]},{"type":"SECONDARY","title":"Creatinine at Week 12.","description":"The creatinine levels are going to be measured at week 12 with standardized techniques.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.01"},{"groupId":"OG001","value":"0.05","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Uric Acid at Week 12.","description":"The uric acid levels are going to be measured at week 12 with standardized techniques.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"243.9","spread":"55.3"},{"groupId":"OG001","value":"339.0","spread":"53.5"}]}]}]},{"type":"SECONDARY","title":"AUC of Glucose at Week 12.","description":"The AUC of glucose will be calculated from the glucose values obtained from the minuted oral glucose tolerance curve at week 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1153","spread":"280"},{"groupId":"OG001","value":"1129","spread":"232"}]}]}]},{"type":"SECONDARY","title":"AUC of Insulin at Week 12.","description":"The AUC will be calculated from the insulin values obtained from the minuted oral glucose tolerance curve at week 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45016","spread":"22147"},{"groupId":"OG001","value":"119704","spread":"46872"}]}]}]},{"type":"SECONDARY","title":"Glucose at Minute 30 at Week 12.","description":"The glucose at minute 30 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"2.0"},{"groupId":"OG001","value":"10.0","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Glucose at Minute 60 at Week 12.","description":"The glucose at minute 60 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":"3.1"},{"groupId":"OG001","value":"11.4","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Glucose at Minute 90 at Week 12.","description":"The glucose at minute 90 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":"3.5"},{"groupId":"OG001","value":"9.9","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Glucose at Minute 120 at Week 12.","description":"The glucose at minute 120 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"2.1"},{"groupId":"OG001","value":"8.8","spread":"2.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Urinary infection"]}}}